Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials : JACC Scientific Expert Panel

Ibanez, Borja ; Aletras, Anthony H. LU orcid ; Arai, Andrew E. ; Arheden, Hakan LU ; Bax, Jeroen ; Berry, Colin ; Bucciarelli-Ducci, Chiara ; Croisille, Pierre ; Dall'Armellina, Erica and Dharmakumar, Rohan , et al. (2019) In Journal of the American College of Cardiology 74(2). p.238-256
Abstract

After a reperfused myocardial infarction (MI), dynamic tissue changes occur (edema, inflammation, microvascular obstruction, hemorrhage, cardiomyocyte necrosis, and ultimately replacement by fibrosis). The extension and magnitude of these changes contribute to long-term prognosis after MI. Cardiac magnetic resonance (CMR) is the gold-standard technique for noninvasive myocardial tissue characterization. CMR is also the preferred methodology for the identification of potential benefits associated with new cardioprotective strategies both in experimental and clinical trials. However, there is a wide heterogeneity in CMR methodologies used in experimental and clinical trials, including time of post-MI scan, acquisition protocols, and, more... (More)

After a reperfused myocardial infarction (MI), dynamic tissue changes occur (edema, inflammation, microvascular obstruction, hemorrhage, cardiomyocyte necrosis, and ultimately replacement by fibrosis). The extension and magnitude of these changes contribute to long-term prognosis after MI. Cardiac magnetic resonance (CMR) is the gold-standard technique for noninvasive myocardial tissue characterization. CMR is also the preferred methodology for the identification of potential benefits associated with new cardioprotective strategies both in experimental and clinical trials. However, there is a wide heterogeneity in CMR methodologies used in experimental and clinical trials, including time of post-MI scan, acquisition protocols, and, more importantly, selection of endpoints. There is a need for standardization of these methodologies to improve the translation into a real clinical benefit. The main objective of this scientific expert panel consensus document is to provide recommendations for CMR endpoint selection in experimental and clinical trials based on pathophysiology and its association with hard outcomes.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
area at risk, clinical trial, edema, endpoint, infarct size, magnetic resonance imaging, myocardial infarction, STEMI
in
Journal of the American College of Cardiology
volume
74
issue
2
pages
19 pages
publisher
Elsevier
external identifiers
  • scopus:85068082015
  • pmid:31296297
ISSN
0735-1097
DOI
10.1016/j.jacc.2019.05.024
language
English
LU publication?
yes
id
987ccd98-25f8-45a9-8257-3ad8efd19186
date added to LUP
2019-07-09 11:47:21
date last changed
2024-12-12 17:45:19
@article{987ccd98-25f8-45a9-8257-3ad8efd19186,
  abstract     = {{<p>After a reperfused myocardial infarction (MI), dynamic tissue changes occur (edema, inflammation, microvascular obstruction, hemorrhage, cardiomyocyte necrosis, and ultimately replacement by fibrosis). The extension and magnitude of these changes contribute to long-term prognosis after MI. Cardiac magnetic resonance (CMR) is the gold-standard technique for noninvasive myocardial tissue characterization. CMR is also the preferred methodology for the identification of potential benefits associated with new cardioprotective strategies both in experimental and clinical trials. However, there is a wide heterogeneity in CMR methodologies used in experimental and clinical trials, including time of post-MI scan, acquisition protocols, and, more importantly, selection of endpoints. There is a need for standardization of these methodologies to improve the translation into a real clinical benefit. The main objective of this scientific expert panel consensus document is to provide recommendations for CMR endpoint selection in experimental and clinical trials based on pathophysiology and its association with hard outcomes.</p>}},
  author       = {{Ibanez, Borja and Aletras, Anthony H. and Arai, Andrew E. and Arheden, Hakan and Bax, Jeroen and Berry, Colin and Bucciarelli-Ducci, Chiara and Croisille, Pierre and Dall'Armellina, Erica and Dharmakumar, Rohan and Eitel, Ingo and Fernández-Jiménez, Rodrigo and Friedrich, Matthias G. and García-Dorado, David and Hausenloy, Derek J. and Kim, Raymond J. and Kozerke, Sebastian and Kramer, Christopher M. and Salerno, Michael and Sánchez-González, Javier and Sanz, Javier and Fuster, Valentin}},
  issn         = {{0735-1097}},
  keywords     = {{area at risk; clinical trial; edema; endpoint; infarct size; magnetic resonance imaging; myocardial infarction; STEMI}},
  language     = {{eng}},
  month        = {{07}},
  number       = {{2}},
  pages        = {{238--256}},
  publisher    = {{Elsevier}},
  series       = {{Journal of the American College of Cardiology}},
  title        = {{Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials : JACC Scientific Expert Panel}},
  url          = {{http://dx.doi.org/10.1016/j.jacc.2019.05.024}},
  doi          = {{10.1016/j.jacc.2019.05.024}},
  volume       = {{74}},
  year         = {{2019}},
}